Drug Profile

ABI 902

Alternative Names: ABI-902

Latest Information Update: 07 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avirmax Biopharma
Class Antiglaucomas; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Glaucoma

Most Recent Events

07 Feb 2025 Avirmax Biopharma plans to file an IND application for glaucoma in the second half of 2026 (Avirmax Biopharma pipeline, February 2025).
12 Feb 2023 ABI 902 is available for licensing as of 12 Feb 2023. https://avirmax.com/biopharma/contact-us/ (Avirmax Biopharma pipeline; February 2023)
12 Feb 2023 Avirmax Biopharma plans a pre-IND evaluation for Glaucoma in second half of 2023 (Avirmax Biopharma pipeline; February 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com